Filing Details

Accession Number:
0001567619-23-005059
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-14 19:40:22
Reporting Period:
2023-03-10
Accepted Time:
2023-03-14 19:40:22
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1048477 Biomarin Pharmaceutical Inc BMRN Pharmaceutical Preparations (2834) 680397820
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1221590 Jacques Jean Bienaime C/O Biomarin Pharmaceutical Inc.
770 Lindaro St.
San Rafael CA 94901
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-10 15,000 $67.81 502,856 No 4 M Direct
Common Stock Disposition 2023-03-10 15,000 $92.28 487,856 No 4 S Direct
Common Stock Acquisiton 2023-03-13 8,000 $67.81 495,856 No 4 M Direct
Common Stock Disposition 2023-03-13 8,000 $90.45 487,856 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to buy Common Stock) Disposition 2023-03-10 15,000 $0.00 15,000 $67.81
Common Stock Stock Option (Right to buy Common Stock) Disposition 2023-03-13 8,000 $0.00 8,000 $67.81
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
157,130 2013-11-15 2023-05-14 No 4 M Direct
149,130 2013-11-15 2023-05-14 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 247,333 Indirect Shares held by Jean-Jacques Bienaime Family Trust
Common Stock 100 Indirect Shares held as UTMA custodian for child
Common Stock 100 Indirect Shares held as UTMA custodian for child
Footnotes
  1. Trade made pursuant to a 10b5-1 plan executed on May 3, 2022.
  2. Trade made pursuant to a 10b5-1 plan executed on November 17, 2022.
  3. Reflects the number of options outstanding after the transactions from this specific stock option grant.